Divis Laboratories Ltd
Divis Laboratories Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #54 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Divi's Laboratories expects steady growth with constant currency growth at around 8.5% to 10% over the near term (Page 13). Divi's Laboratories aims for consistent double-digit growth, with an 8.5% constant currency growth achieved for 9 months ended December 2025.
From Divis Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Divi's Laboratories expects steady growth with constant currency growth at around 8.5% to 10% over the near term (Page 13).
- Growth will be supported by a broad basket of custom synthesis (CS) products in various patent phases, balancing late life cycle, secondary source, and new product launches (Pages 9 and 13).
- Presence of multiple molecules in Phase II and Phase III clinical trials underpins a stable long-term growth trajectory (Page 13).
- Expansion of dedicated manufacturing blocks and peptide capacities is ongoing, with commercial scale readiness for new custom synthesis products expected post-2027 (Pages 12 and 17).
2 more points from Divis Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Divis Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex of ₹1,900 crores for FY '26 intimated to SEBI, slightly below initial guidance of ₹2,000 crores.
- Capex focus on Unit 1 and Unit 3, especially Unit 3, undergoing multiple design phases.
- Future capex plans will be announced to SEBI once a futuristic outlook is finalized, particularly for heavy investments.
- Evaluation ongoing for Phase 2 expansion of Kakinada Unit 3 with 4 production blocks, decision pending.
- Investments continuing on dedicated custom synthesis (CS) projects; commercialization expected by end of FY 2027.
2 more points from Divis Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Divis Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is engaged in several custom synthesis projects, with 3 dedicated molecules currently validated and undergoing regulatory approvals.
- Validations for some products are completed, while others are ongoing or planned in the near term.
- Commercialization of these products is expected to start around the second half of FY '27, post regulatory approvals.
- Production blocks are mostly multipurpose, enabling quick scaling or adaptation for new products as needed.
2 more points from Divis Laboratories Ltd's call on order book
Create a free account to keep reading this call
Divis Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.8K Cr, net profit ₹751 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Divi's Lab.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Guj. Themis Bio. (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Divis Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Divis Laboratories Ltd Q3 FY26 results?
Divi's Laboratories expects steady growth with constant currency growth at around 8.5% to 10% over the near term (Page 13). Divi's Laboratories aims for consistent double-digit growth, with an 8.5% constant currency growth achieved for 9 months ended December 2025.
What is Divis Laboratories Ltd share price analysis?
Divis Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 75.5 with a market cap of ₹225,038 Cr. Investors should review the full earnings analysis for detailed insights.
Is Divis Laboratories Ltd planning capital expenditure?
Capex of ₹1,900 crores for FY '26 intimated to SEBI, slightly below initial guidance of ₹2,000 crores.
Keep Divis Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.